Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 8/20 | 0.43 |
| ▸ | CA1 | P00915 | 8/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA4 | P22748 | 8/20 | 0.43 |
| ▸ | CA7 | P43166 | 8/20 | 0.43 |
| ▸ | CA9 | Q16790 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4371409 | 0.91 | CA12 (0.43) | GAAADRA1ACA12CA1CA2 | |
| SCHEMBL4370320 | 0.89 | CA12 (0.42) | GAAADRA1ACA12CA1CA2 | |
| SCHEMBL4380239 | 0.89 | CA12 (0.46) | GAAADRA1ACA12CA1CA2 | |
| SCHEMBL4379844 | 0.89 | KMT2A (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4370293 | 0.87 | KMT2A (0.47) | GAACA12CA1CA2CA4 | |
| SCHEMBL4371258 | 0.86 | KMT2A (0.49) | GAAALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL4374705 | 0.85 | BTK (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4373586 | 0.85 | BTK (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4379870 | 0.84 | FLT1 (0.51) | — | |
| SCHEMBL4379291 | 0.82 | KMT2A (0.44) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625896-B2 | Pyridylsulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | claimed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | claimed |
| US-7625896-B2 | Pyridylsulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | TPMT, BPNT1, SLC6A3 | GAA 3480/4885ADRA1A 617/4885CA12 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.